scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.IJROBP.2018.08.027 |
P698 | PubMed publication ID | 30149056 |
P50 | author | Hong Wang | Q37610192 |
P2093 | author name string | Dwight E Heron | |
David A Clump | |||
Steven A Burton | |||
Ronny Kalash | |||
Daniel P Petro | |||
Philip Sutera | |||
David D'Ambrosio | |||
Alina Mihai | |||
P433 | issue | 1 | |
P921 | main subject | phase II clinical trial | Q42824440 |
multicenter clinical trial | Q6934595 | ||
P304 | page(s) | 116-122 | |
P577 | publication date | 2018-08-25 | |
P1433 | published in | International Journal of Radiation Oncology Biology Physics | Q2296252 |
P1476 | title | Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer | |
P478 | volume | 103 |
Q92747874 | Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer |
Q64055804 | Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer |
Q93129302 | NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy |
Q90706179 | Oligometastatic head and neck cancer: Comprehensive review |
Q64063425 | Peripheral memory and naïve T cells in non-small cell lung cancer patients with lung metastases undergoing stereotactic body radiotherapy: predictors of early tumor response |
Q89520971 | Signals from SABR-COMET time to move on to phase III studies |
Q104693486 | Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study |
Q100573253 | Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers |
Q92605873 | The Role of Local Treatment in Oligometastatic and Oligoprogressive Cancer |
Search more.